| __timestamp | Neurocrine Biosciences, Inc. | Telix Pharmaceuticals Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 14400000 | 22622695 |
| Thursday, January 1, 2015 | 33800000 | 24863028 |
| Friday, January 1, 2016 | 35900000 | 21351001 |
| Sunday, January 1, 2017 | 1254000 | 53837297 |
| Monday, January 1, 2018 | 4889000 | 16080096 |
| Tuesday, January 1, 2019 | 7400000 | 18525736 |
| Wednesday, January 1, 2020 | 10100000 | 2024000 |
| Friday, January 1, 2021 | 14300000 | 2548000 |
| Saturday, January 1, 2022 | 23200000 | 61556000 |
| Sunday, January 1, 2023 | 39700000 | 188157000 |
| Monday, January 1, 2024 | 34000000 |
Unlocking the unknown
In the ever-evolving world of biotechnology, understanding the cost of revenue is crucial for assessing a company's financial health. Neurocrine Biosciences, Inc. and Telix Pharmaceuticals Limited, two prominent players in the industry, have shown contrasting trends over the past decade. From 2014 to 2023, Neurocrine's cost of revenue has seen a steady increase, peaking in 2023 with a 175% rise from its 2014 figures. Meanwhile, Telix Pharmaceuticals experienced a more volatile journey, with a staggering 730% increase in 2023 compared to 2014. This dramatic rise highlights Telix's aggressive expansion and investment in its product pipeline. The data reveals a fascinating narrative of strategic growth and financial management, offering valuable insights for investors and industry analysts alike. As these companies continue to innovate, their cost of revenue will remain a key indicator of their operational efficiency and market strategy.
Cost Insights: Breaking Down Sanofi and Telix Pharmaceuticals Limited's Expenses
Analyzing Cost of Revenue: United Therapeutics Corporation and Neurocrine Biosciences, Inc.
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and Incyte Corporation
Cost Insights: Breaking Down Neurocrine Biosciences, Inc. and Dr. Reddy's Laboratories Limited's Expenses
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and ADMA Biologics, Inc.
Comparing Cost of Revenue Efficiency: Neurocrine Biosciences, Inc. vs Agios Pharmaceuticals, Inc.
Comparing Cost of Revenue Efficiency: Neurocrine Biosciences, Inc. vs Geron Corporation
Analyzing Cost of Revenue: Neurocrine Biosciences, Inc. and Travere Therapeutics, Inc.
Neurocrine Biosciences, Inc. vs Viridian Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: BioMarin Pharmaceutical Inc. and Telix Pharmaceuticals Limited
Cost of Revenue: Key Insights for Exelixis, Inc. and Telix Pharmaceuticals Limited
Comparing Cost of Revenue Efficiency: Cytokinetics, Incorporated vs Telix Pharmaceuticals Limited